Xiangyang Lu
CEO & Executive ChairmanDr. Xiangyang Lu, also known as Chris, Ph.D. serves as Executive Director at Laekna, Inc. since May 2022, Director since July 29, 2016 and also serves as its Chief Executive Officer & Chairman. He is a Venture Partner at Frontline BioVentures since 2016 specializing in life science. Prior to joining Frontline BioVentures, Dr. Lu was an Executive Director of the Drug Discovery Research Department in Novartis Institute for Biomedical Research. He has over 20 years of experience in research and development of innovative molecular biological drugs. Dr. Lu initiated and led low-molecular-weight and biologics projects and advanced them to clinical stages. He is the co-inventor of innovative medicines. Dr. Lu received a VIVA award as Novartis Leading Scientist in 2012 for his outstanding achievement in drug discovery. In 2013, an antibody discovered by Dr. Lu’s research team was given by the Food and Drug Administration the “Breakthrough Therapy Designation” for muscle diseases. He was a group leader at Wyeth and a starting scientist at Ontogeny. Dr. Lu has over ten issued U.S. patents and more than twenty academic articles published. He is a member of American Association for the Study of Liver Diseases, a member of American Association for Cancer Research and a member of BayHelix group. Dr. Lu completed his post-doctoral training with Mark Ptashne at Harvard University. He holds a Ph.D. in Biochemistry from University of North Carolina at Chapel Hill. Dr. Lu received his M.S. and B.S. degrees in Molecular Biology from Nankai University.
Positions
- Company NameLaekna, Inc.Stock Code02105PositionCEO & Executive Chairman
